284 related articles for article (PubMed ID: 34831287)
1. PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells.
Udawant S; Litif C; Lopez A; Gunn B; Schuenzel E; Keniry M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831287
[TBL] [Abstract][Full Text] [Related]
2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
3. NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Vazquez N; Lopez A; Cuello V; Persans M; Schuenzel E; Innis-Whitehouse W; Keniry M
Cancer Treat Res Commun; 2021; 27():100340. PubMed ID: 33636591
[TBL] [Abstract][Full Text] [Related]
4. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Ma J
Nagoya J Med Sci; 2019 Feb; 81(1):93-102. PubMed ID: 30962658
[TBL] [Abstract][Full Text] [Related]
7. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
[TBL] [Abstract][Full Text] [Related]
8. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.
Agliano A; Balarajah G; Ciobota DM; Sidhu J; Clarke PA; Jones C; Workman P; Leach MO; Al-Saffar NMS
Oncotarget; 2017 Jul; 8(29):47969-47983. PubMed ID: 28624789
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
10. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
Firat E; Niedermann G
Oncotarget; 2016 Aug; 7(34):54883-54896. PubMed ID: 27448972
[TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
[TBL] [Abstract][Full Text] [Related]
16. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
17. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
20. The PI3K pathway impacts stem gene expression in a set of glioblastoma cell lines.
Martinez E; Vazquez N; Lopez A; Fanniel V; Sanchez L; Marks R; Hinojosa L; Cuello V; Cuevas M; Rodriguez A; Tomson C; Salinas A; Abad M; Holguin M; Garza N; Arenas A; Abraham K; Maldonado L; Rojas V; Basdeo A; Schuenzel E; Persans M; Innis-Whitehouse W; Keniry M
J Cancer Res Clin Oncol; 2020 Mar; 146(3):593-604. PubMed ID: 32030510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]